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Summary.-The in vivo biological activity of various fractions and components of haematoporphyrin derivative (HpD) have been determined by measuring the depth of necrosis of implanted tumours in mice exposed to light after the administration of standard doses of porphyrins dissolved in alkali.
In this assay, haematoporphyrin, hydroxyethylvinyldeuteroporphyrin and protoporphyrin are inactive, but the mono-and di-acetates of haematoporphyrin (which are major components of HpD) and acetoxyethylvinyldeuteroporphyrin are Active.
However, the situation appears to be more complex than this. The normal method for preparing HpD for injection involves an alkali treatment which causes hydrolysis and elimination of the acetoxy functions, and the only recognized products (haematoporphyrin, hydroxyethylvinyldeuteroporphyrin and protoporphyrin) are inactive in the in vivo assay. It is concluded that the active component here is a porphyrin, possibly a dimer or oligomer, which is retained on the column during the normal separation by HPLC. This conclusion is supported by the observations that (i) the crude material obtained from the spent column is active without further alkali treatment, and (ii) activity develops over 30 min, when HpD or the mono-or diacetates of haematoporphyrin are treated with sodium bicarbonate in aqueous DMSO.
The advantages of working with a pure substance (e.g. haematoporphyrin diacetate) rather than a mixture (HpD) are stressed.
HAEMATOPORPHYRIN DERIVATIVE (HpD) has promise as a photosensitizing agent for the treatment of neoplasms accessible to light. On injection in vivo, it causes tumours exposed to intense light in the visible range to undergo rapid necrosis. The combination of HpD and light treatment has been applied with some success in the therapy of superficial tumours in man and laboratory rodents (Diamond et al., 1972; Kelly et al., 1975; Dougherty et al. 1978 ) and, with the aid of fibre optic light-conducting systems, in treating deep tumours in domestic animals (Dougherty et al., 1981) .
HpD is prepared by treating commercial haematoporphyrin dihydrochloride with sulphuric acid in glacial acetic acid (Lipson & Baldes, 1960; Lipson et al., 1961) . It is a complex mixture, and it is clearly important to identify the components responsible for its anti-tumour effects in vivo and to use these in a pure form. HpD has therefore been fractionated by preparative high-pressure liquid chromatography (Bonnett et al., 1978 (Bonnett et al., , 1980 (Bonnett et al., , 1981 and we now report the activities of the various components, as judged by an in vivo assay using a transplantable mouse tumour.
MATERIALS AND METHODS
HpD and other porphyrins.-HpD was prepared from haematoporphyrin dihydrochloride (Koch Light, Colnbrook). Full details of the preparation and fractionation using high-pressure liquid chromatography (HPLC) are given in Bonnett et al. (1981) which also records the preparation of authen- 1) and measurement of the depth of necrosis usually presented no great difficulty if measurements were made over the centre of the tumour, where the skin surface was at right angles to thle light beam. About 600 tumours -were used in the w-ork summarized lhere. Results from 22 of these were excluded from analysis because of interference by superficial ulceration or spontaneous necrosis (deep in the tumour and distributed irregularly writhout relation to the direction of illumination). W1here necrosis due to illumination involved the whole tumour thickness (which occurred in about 1 tumour in 9) it was assigned a depth equal to the tumour thickness.
RESULTS

Chrormatographic separation
The separation of the major components of HpD on a preparative scale by HPLC has been described (Bonnett et al., 1981) and a typical separation is shown, with the components and fractions identified, in Fig. 2 . Fig. 3 Biological activity of HpD fractions dissolved in alkali Two such separations were carried out for the purpose of biological testing.
Certain minor fractions which were obtained in insufficient quantity for individual testing were combined (for a given separation) as shown in Table I , where the results for the 2 experiments are compared. The 2 experiments (i.e. separation plus a complete set of bioassays) were done at an interval of 6 months with 2 different batches of HpD. During this interval the focusing of the light source was improved, so that, while the mean depth of damage with a standard dose of HpD (40 mg/kg) was 1-4 + 0-6 mm for the first set of observations, it had increased to 36 + 0-9 mm by the time the second set was made. Results for tests on the HpD fractions are therefore expressed in Table I as fractions of the depth of damage concurrently observed with the standard dose of HpD.
No activity was found in the polar components (which emerged from the column first, and which were combined with other minor fractions). Haematoporphyrin and hydroxyethylvinyldeuteroporphyrin (isomers) were also inactive. On the other hand haematoporphyrin diacetate, haematoporphyrin monoacetate (isomers) and acetoxyethylvinyldeuteroporphyrin (isomers), and interfraction cuts containing these compounds were all active, and did not differ materially in activity at the doses given.
Biological activity of known hydrolysis products of HpD (Table 11) HpD is commonly prepared for injection by treating it with 0 1M NaOH for l h at room temperature (Dougherty et al., 1978) . Under these conditions the simple porphyrin acetates do not survive, but haematoporphyrin (1), hydroxyethylvinyldeuteroporphyrin (4 and 5), and protoporphyrin (9) are the major recognized constituents (Bonnett et al., 1980) . These compounds, prepared by standard methods, were tested in a separate series of experiments. Samples of haematoporphyrin (pure, and the commercial dihydrochloride) dissolved readily in DMSO-bicarbonate-PBS, but were found (Table II) . Effect of time on the biological activity of porphyrin acetates in aqueous bicarbonate
In view of the effect of base on the composition of HpD, the bioassay was extended to HpD solutions in which solvolysis and elimination reactions were minimized. Three types of solution were used as follows: (i) HpD in neat DMSO, given in a volume of 0 01-0 02 ml/10 g (ii) HpD in DMSO diluted in PBS (pH 7.3) or in 05%o sodium acetate in PBS and (iii) HpD in DMSO diluted in the usual way with bicarbonate-PBS but injected within 1 min of dilution. All these preparations showed biological activity (Table III) which was less than that observed with the bicarbonate-saline preparation administered in the normal way (when it was injected -30 min after dilution). Timed injections showed that HpD developed biological activity in aqueous DMSO-bicarbonate-PBS solution; activity came to a maximum in 30 min, and did not then change appreciably over 3 days (Table III) . It was this observation that led to the adop- 
(8) 
(6) (6) (Table IV) . Experiments on bicarbonate-PBS solutions of HpD stored in the refrigerator showed unimpaired activity over several months.
Thus these experiments indicated that the biological activity of HpD and its main constituents, haematoporphyrin mono-and di-acetates, increased on exposure to base. However, the recognized constituents of alkali-treated HpD that passed through a HPLC column were inactive. The most likely explanation was that the active constituents of alkalitreated HpD were retained on the column. The following experiment was therefore performed.
Fractionation of alkali-treated HpD
HpD (463 mg) was stirred in 0dIM NaOH (20 ml) at room temperature and in subdued light for 3 h. The solution was neutralized with 2M HC1 and then acidified with a few drops of glacial acetic acid to induce precipitation. Saturated aqueous NaCl (10 ml) was added, and the mixture was cooled. The precipitate was removed and washed (with water) at the centrifuge, and dried in vacuo.
A portion of the product was chromatographed on Lichroprep 195 g, packed in methanol at 10 bar, conditioned with 1600 ml of elutriant) using the Jobin-Yvon Chromatospac 10. The porphyrin mixture was applied in tetrahydrofuran (2.5 ml) + methanol (1 ml) +elutriant (3 ml), and eluted with methanol-water 
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eluate was diluted with ethyl acetate (300 ml), saturated NaCi (180 ml) was added, and the pH was adjusted to -4-5. After equilibration the organic layer was removed, and the aqueous layer was re-extracted with a second portion of ethyl acetate. The organic extracts were combined and washed with saturated NaCl solution (100 ml), 500o saturated NaCl solution (100 ml) and distilled water (100 ml). The solvent was removed under vacuum to give Fraction E (7 mg).
As the HpD thus fractionated had already been "activated" by alkali, it was reasoned that any active constituent should be effective in vivo if injected without further exposure to alkali. Accordingly, the dried fractions were dissolved in DMSO and injected i.p. in volumes of 0-01 ml/10 g body wt. Freezedried unfractionated alkali-activated HpD was used as a standard. The results are shown in Fig. 4 (Kessel, 1977; Sery, 1979; Christensen, 1981) and protoporphyrin sensitizes cultured human and mouse tumour cells and chronic lymphocytic leukaemia lymphocytes in vitro (Malik and Djaldetti, 1980a, b) Initially, our in vivo tests involved comparing the growth rates of treated and untreated tumours. These are not reported here because it became apparent that the effect of treatment was greatly dependent on tumour geometry. Light intensity falls off more or less exponentially with depth of tissue (Eichler et al., 1977; Dougherty et al., 1978) so that the damaged proportion of a tumour depends very much on its diameter parallel to the light beam. A treatment that destroys, say, the superficial half of one tumour might completely destroy another tumour of the same volume but half the thickness. The growth curve of the first tumour might show merely a delay of one doubling time, whereas the second tumour would show complete regression. Measurements of growth curves are therefore likely to yield useful results only with tumours which have been highly selected for uniformity of size and shape. In contrast,the direct measurement of the depth of tumour necrosis suffers no such limitations. In our view this provides a satisfactory measure of the overall effectiveness of the treatment, though it is possible that an additional effect is mediated by the impairment of reproductive integrity of cells in the tumour beyond the limit of obvious necrosis Christensen, 1981) .
The present experiments have gone part of the way towards identifying the active constituents of HpD. In the in vivo biological assay, haematoporphyrin (1), the hydroxyethylvinyldeuteroporphyrin isomers (4 and 5), and protoporphyrin (9) show no activity, whereas the porphyrin acetates [haematoporphyrin monoacetate (2, 3), haematoporphyrin diacetate (6) and acetoxyethylvinyldeuteroporphyrin (7, 8) ] are all active, and have rather similar activities. Were this the end of the matter, it would be tempting to relate the biological activity to the expected alkylating action of the pseudobenzylic acetate functions.
However, HpD is activated by the presence of base (bicarbonate, hydroxide), and its 2 major constituents (the haematoporphyrin mono-and di-acetates) are not active until they have been treated by base (bicarbonate , Table IV ). Yet the products of the alkali activation of HpD, identified by HPLC (1, 4, 5, 9) are not active in the in vivo assay. Hence it appears necessary to postulate an additional type of component which is not separated by our normal HPLC technique. Support for this view comes from the experiment in which HpD was treated with NaOH, and then fractionated by HPLC.
Of fractions collected in the normal way, only Fraction A had moderate activity, evidently not due to its main constituent, haematoporphyrin. However, when the spent column was treated with two solvents of considerable eluting power, to bring off, in 2 fractions, material strongly retained by the column, one of these (Fraction D, Fig. 3 ) was found, when dissolved in DMSO and injected without further base treatment, to have activity similar to that of base-activated unfractionated HpD.
The chemical interpretation of this remains to be determined. It seems likely that a porphyrin component, presumably a dimer or oligomer, of higher mol. wt has been formed, and this is now being studied further. Since the O-acetates are precursors of the biologically active materials, and these compounds appear to be stable, it seems likely that C-O or C-C bonds have been formed between mole- cules. Some possibilities are shown in Fig. 5 . Finally it is noted that special caution with regard to purity is required in tests on porphyrins, especially with haematoporphyrin and its relatives. For example, Granelli et al. (1975) found that commercial haematoporphyrin photosensitized rat glioma cells in vitro, but reported that only about 50% of the material used was haematoporphyrin. Again, Henderson et al. (1980) found that the fluorescence induced in tumours by haematoporphyrin they had prepared was due largely to contamination with haematoporphyrin monoacetate. As far as the use of HpD is concerned, it would appear advisable to use a pure component of HpD of known activity instead of the variable mixture at present in use. Haematoporphyrin diacetate (6) would appear to be the most suitable for this purpose.
